Regulatory T cells (Tregs) play a role in the induction and maintenance of tolerance, as well as in modulating aberrant immune responses. While expanded Tregs have been used in clinical trials, they are polyclonal and the frequency of specific Tregs is very low. To overcome this issue, we have endeavored to "specify" Tregs by engineering them to express receptors that can recognize a given antigen and applied this protocol in autoimmunity, hemophilia and allergy. Thus, we have used retroviral transduction of a specific T cell receptor, single-chain variable fragments (Fvs), or antigen domains in Tregs to achieve this goal. This review summarizes our steps to achieve the ultimate goal of modulating human diseases.

中文翻译：

---

T细胞的免疫耐受性基因工程。

调节性T细胞（Tregs）在诱导和维持耐受性以及调节异常的免疫反应中发挥作用。尽管扩展的Treg已用于临床试验，但它们是多克隆的，特异性Treg的频率非常低。为了克服这个问题，我们努力通过工程化Treg来表达能够识别给定抗原的受体，从而“指定” Treg，并将该方案应用于自身免疫，血友病和过敏。因此，我们使用逆转录病毒转导特定T细胞受体，单链可变片段（Fvs）或Tregs中的抗原结构域来实现这一目标。这篇综述总结了我们实现调节人类疾病最终目标的步骤。